Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 12, 2015, Pages 2229-2240

  Inwald, E C ^a   Koller, M ^a   Klinkhammer Schalke, M ^b   Zeman, F ^a   Hofstadter F ^c   Lindberg, P ^b   Gerstenhauer, M ^b   Schuler S ^a   Treeck, O ^a   Ortmann, O ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c JOHANNES KEPLER UNIVERSITY LINZ   (Austria)

Author keywords

Breast cancer; Cancer registry; Endocrine therapy; Overall survival; Steroid hormone receptor

Indexed keywords

STEROID RECEPTOR; TRASTUZUMAB; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER REGISTRY; COHORT ANALYSIS; FEMALE; FOLLOW UP; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; OUTCOME ASSESSMENT; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; SURVIVAL RATE; SYSTEMIC THERAPY; ADJUVANT CHEMOTHERAPY; AGED; BREAST NEOPLASMS; CANCER GRADING; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CASE CONTROL STUDY; COMPARATIVE STUDY; DRUG EFFECTS; ENDOCRINE SYSTEM; ENZYME IMMUNOASSAY; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; REGISTER; TUMOR INVASION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AROMATASE INHIBITORS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; ENDOCRINE SYSTEM; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POSTMENOPAUSE; PREMENOPAUSE; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGISTRIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84946479949     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-2025-z     Document Type: Article

References (31)

1. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JGM, Sahmoud T (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139
2. Baum M, Hackshaw A, Houghton J, Rutqvist Fornander T, Nordenskjold B, Nicolucci A, Sainsbury R (2006) Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study. Eur J Cancer 42:895–904
3. Chlebowski RT, Kim J, Haque R (2014) Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. Cancer Prev Res (Phila) 7:378–387
4. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C, Intergroup Exemestane Study (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092
5. Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, Sainsbury R (2007) Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369:1711–1723
6. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar Medeiros, Hugo Victor, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou M, Inbar M, Khaled H, Kielanowska J, Kwan W, Mathew BS, Mittra I, Muller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805–816
7. Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19:322–328
8. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509–518
9. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) et al (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717
10. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771–784
11. Ejlertsen B, Jensen M, Mouridsen HT (2014) Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer. Acta Oncol 53:174–185
12. Friese CR, Pini TM, Li Y, Abrahamse PH, Graff JJ, Hamilton AS, Jagsi R, Janz NK, Hawley ST, Katz SJ, Griggs JJ (2013) Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat 138:931–939
13. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802
14. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep Fred C G, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795
15. Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, Ortmann O (2013) Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat 139:539–552
16. Inwald EC, Ortmann O, Zeman F, Koller M, Hofstädter F, Gerstenhauer M, Klinkhammer-Schalke M (2014) Guideline concordant therapy prolongs survival in HER2-positive breast cancer patients: results from a large population-based cohort of a cancer registry. Biomed Res Int 2014:137304
17. Kolberg H, Lüftner D, Lux M, Maass N, Schütz F, Fasching P, Fehm T, Janni W, Kümmel S (2012) Breast Cancer 2012 - New Aspects. Geburtsh Frauenheilk 72:602–615
18. Kreienberg R, Albert U, Follmann M, Kopp IB, Kühn T, Wöckel A (2013) Interdisciplinary GoR level III guidelines for the diagnosis, therapy and follow-up care of breast cancer: short version-AWMF registry no.: 032-045OL AWMF-register-nummer: 032-045OL-Kurzversion 3.0, Juli 2012. Geburtshilfe Frauenheilkd 73:556–583
19. Lux M, Maass N, Schütz F, Schwidde I, Fasching P, Fehm T, Janni W, Kümmel S, Kolberg H, Lüftner D (2013) Breast cancer 2013: interpretation of new and known data. Geburtsh Frauenheilk 73:584–598
20. Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108:1515–1524
21. Melcher C, Scholz C, Jäger B, Hagenbeck C, Rack B, Janni W (2012) Breast cancer: state of the art and new findings. Geburtsh Frauenheilk 72:215–224
22. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS et al (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371:107–118
23. Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Lonati V, Barni S (2013) Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials. Breast Cancer Res Treat 140:233–240
24. Prechtel K, Prechtel D (2001) Current standards for the diagnosis of breast carcinoma in routine practice. Pathologe 22:281–284
25. Pritchard KI, Bergh J, Burstein HJ (2012) Update of the oxford overview: new insight and perspectives in the era of personalized medicine. Am Soc Clin Oncol Educ Book 2012:71–79
26. Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138–140
27. Stanton AL, Petrie KJ, Partridge AH (2014) Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry. Breast Cancer Res Treat 145:525–534
28. Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757
29. Thürlimann B, Price KN, Gelber RD, Holmberg SB, Crivellari D, Colleoni M, Collins J, Forbes JF, Castiglione-Gertsch M, Coates AS, Goldhirsch A (2009) Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res Treat 113:137–144
30. Untch M, Gerber B, Harbeck N, Jackisch C, Marschner N, Möbus V, von Minckwitz G, Loibl S, Beckmann MW, Blohmer J, Costa S, Decker T, Diel I, Dimpfl T, Eiermann W, Fehm T, Friese K, Jänicke F, Janni W, Jonat W, Kiechle M, Köhler U, Lück H, Maass N, Possinger K, Rody A, Scharl A, Schneeweiss A, Thomssen C, Wallwiener D et al (2013) 13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus-opinion of a german team of experts (zurich 2013). Breast Care (Basel) 8:221–229
31. Van Ewijk RJG, Schwentner L, Wöckel A, König J, Kreienberg R, Blettner M (2013) Trends in patient characteristics, treatment and survival in breast cancer in a non-selected retrospective clinical cohort study of 2,600 patients. Arch Gynecol Obstet 287:103–110